Report : South America Hemodialysis and Peritoneal Dialysis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Hemodialysis and Peritoneal Dialysis), Product (Devices, Consumables, and Services), and End User (Hospital-Based and Home-Based)

At 6.5% CAGR, the South America hemodialysis and peritoneal dialysis market is speculated to be worth US$ 11,772.43 million by 2028, says Business Market Insights   

According to Business Market Insights’ research, the South America hemodialysis and peritoneal dialysis market was valued at US$ 8,059.69 million in 2022 and is expected to reach US$ 11,772.43 million by 2028, registering an annual growth rate of 6.5% from 2022 to 2028. Home care dialysis being given preference and major players adopting new market strategies are the critical factors attributed to the market expansion.        

Home hemodialysis (HHD) is a kidney replacement modality for patients with end-stage kidney disease (ESKD) that can be performed safely in the patient’s home environment. It requires the assistance of a trained caregiver or qualified hemodialysis nurse. The frequency of treatment for HHD can vary as per the patient. HHD can be performed as conventional HHD, with treatments 3 days a week for 3 to 4 hours or longer each time. It can also be performed as a short daily HHD, occurring 5 to 7 times a week for a shorter duration. Lastly, it can be performed overnight as nocturnal HHD, where treatments normally last 6 to 8 hours. New, easy-to-use machines are being developed for home hemodialysis. These are easier to set up, clean, and disinfect. Although the increasing reimbursement of home dialysis would seem to be an appropriate strategy to stimulate uptake of these modalities, evidence from regions that offer high reimbursement rates for peritoneal dialysis (PD) suggests that the success of this strategy is variable.  

On the contrary, various risks and complications associated with dialysis hurdles the growth of South America hemodialysis and peritoneal dialysis market.

Based on type, the South America hemodialysis and peritoneal dialysis market is bifurcated into hemodialysis and peritoneal dialysis. The former held 86.6% market share in 2022, amassing US$ 6,959.79 million. It is projected to garner US$ 10,317.43 million by 2028 to expand at 6.8% CAGR during 2022–2028.       

Based on product, the South America hemodialysis and peritoneal dialysis market is segmented into devices, consumables, and services. With 56.8% share of the domain, the services segment dominated the market in 2022. It accrued US$ 4,576.63 million in 2022 and is estimated to generate US$ 6,641.18 million by 2028 to grow at a CAGR of 6.4% over the forecast period.       

Based on end user, the South America hemodialysis and peritoneal dialysis market is segmented into hospital-based and home-based. The hospital-based segment held a larger share in 2022 with a market share of 79.9%. Further it accrued US$ 6,454.08 million in 2022 and is expected to reach at US$ 5,588.28 million at a decent CAGR of 3.9% during the forecast period.   

Our regional analysis states that the Rest of South America captured 38.0% market share in 2022. It was assessed at US$ 3,065.10 million in 2022 and is likely to hit US$ 4,392.29 million by 2028, exhibiting a CAGR of 6.2% during the forecast period.    

Key players dominating the South America hemodialysis and peritoneal dialysis market are Asahi Kasei Medical Co., Ltd.; B. Braun Melsungen AG; Baxter International Inc.; DaVita Inc.; Dialife SA; Diaverum; Fresenius Medical Care AG & Co KGaA; and Rockwell Medical, Inc. and among others.

The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance:

  • Baxter International Inc. presented a new data at the "World Congress of Nephrology" indicating the use of Baxter’s Sharesource remote patient management platform with an automated peritoneal dialysis (APD) cycler that may improve the clinical effectiveness of home kidney patients care by extending their time on therapy by 3.4 months.
  • B. Braun Melsungen AG acquires a specialist in the preparation of dialysis concentrates, Intermedt Medizin & Technik GmbH. The acquisition has helped B. Braun Melsungen AG to complete the extensive product portfolio of its B. Braun Avitum division as a systems provider for extracorporeal blood treatment (dialysis).  

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id

Download Free PDF Brochure